/
MXCT
$1.24+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$132.8M
107M shares
52-week range
$0.64 – $2.37
35% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
CS
Borrow rate
0.44%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-15.76
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.7M | $21.6M | $26.2M | $33.9M | $44.3M | $41.3M | $38.6M | $33.0M |
| Cost of revenue | $1.8M | $2.5M | $2.8M | $3.6M | $5.1M | $4.7M | $7.1M | $6.2M |
| Gross profit | $14.8M | $19.1M | $23.4M | $30.2M | $39.2M | $36.5M | $31.5M | $26.8M |
| Gross margin | 89.0% | 88.4% | 89.4% | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| R&D | $11.2M | $17.6M | $17.7M | $15.4M | $19.5M | $23.8M | $22.2M | $20.8M |
| Operating income | −$8.4M | −$12.4M | −$11.1M | −$18.2M | −$27.4M | −$48.3M | −$51.2M | −$45.3M |
| EBITDA | −$7.9M | −$11.6M | −$9.9M | −$16.6M | −$20.7M | −$33.8M | −$36.3M | −$39.5M |
| Net income | −$8.9M | −$12.9M | −$11.8M | −$19.1M | −$23.6M | −$37.9M | −$41.1M | −$44.6M |
| Net margin | -53.2% | -59.6% | -45.2% | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| EPS (diluted) | -0.17 | -0.24 | -0.18 | -0.22 | -0.19 | -0.37 | -0.39 | -0.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $31M | $-0.28 | $-0.29–$-0.26 | 3 |
| 2027 | $38M | $-0.26 | $-0.27–$-0.24 | 3 |
| 2028 | $45M | $-0.20 | $-0.21–$-0.19 | 1 |
| 2029 | $82M | $-0.11 | $-0.12–$-0.10 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
MaxCyte, Inc. Common Stock
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
www.maxcyte.com- Employees
- 91
- IPO / List date
- Dec 5, 2019
- HQ
- ROCKVILLE, MD
Held by traders on TradeandTell
No one on the platform currently holds MXCT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,993,200 | $1.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MXCT yet.
